Travere Therapeutics (TVTX) Misses Q2 EPS by 6c, beats revenue

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($1.13), $0.06 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $57 million versus the consensus estimate of $53.71 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Travere Therapeutics (TVTX) PT Raised to $65 at Wells Fargo
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital